Prospective trial assesses pentraxin 3 in plasma and BALF for diagnosing invasive pulmonary aspergillosis, indicating its potential benefits.
: Both BALF and plasma PTX3 serve as valuable adjunctive biomarkers for IPA in non-neutropenic patients. PTX3 markedly improves diagnostic sensitivity, especially when combined with GM, supporting its role in the early and rapid rule-out of IPA.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: